Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Apr;24(2):146-158.
doi: 10.1007/s11102-020-01092-6. Epub 2020 Oct 21.

HOMA-IR in acromegaly: a systematic review and meta-analysis

Betina Biagetti  1 , Anna Aulinas  2   3   4 , Anna Casteras  1 , Santiago Pérez-Hoyos  5 , Rafael Simó  6
Affiliations
Meta-Analysis

HOMA-IR in acromegaly: a systematic review and meta-analysis

Betina Biagetti et al. Pituitary. 2021 Apr.

Abstract

Purpose: This review is aimed at examining whether the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is higher in Caucasian, adult, treatment-naïve patients with acromegaly (ACRO) than in the reference population independently of diabetes presence and to evaluate the impact of treatment [surgery and somatostatin analogues (SSAs)] on its assessment.

Methods: We systematically reviewed in PubMed and Web of Science from July 1985 to December 2019, registered with the code number CRD42020148737. The inclusion criteria comprised studies conducted in Caucasian adult treatment-naïve patients with active ACRO in whom HOMA-IR or basal insulin and glucose were reported. Three reviewers screened eligible publications, extracted the outcomes, and assessed the risk of biases.

Results: Of 118 originally selected studies, 15 met the inclusion criteria. HOMA-IR was higher in ACRO than the reference population, with mean difference and (95% confidence intervals) of 2.04 (0.65-3.44), even in ACRO patients without diabetes, 1.89 (1.06-2.73). HOMA-IR significantly decreased after treatment with either surgery or SSAs - 2.53 (- 3.24- - 1.81) and - 2.30 (- 3.05- - 1.56); respectively. However, the reduction of HOMA-IR due to SSAs did not improve basal glucose.

Conclusion: HOMA-IR in treatment-naïve ACRO patients is higher than in the reference population, even in patients without diabetes. This finding, confirms that insulin resistance is an early event in ACRO. Our results also suggest that HOMA-IR is not an adequate tool for assessing insulin resistance in those patients treated with SSAs.

Keywords: Acromegaly; Diabetes mellitus; HOMA; Insulin resistance; Meta-analysis.

PubMed Disclaimer

References

    1. Kasayama S, Otsuki M, Takagi M et al (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549–555 - DOI
    1. Janssen JAMJL (2020) Mechanisms of putative IGF-I receptor resistance in active acromegaly. Growth Horm IGF Res 52:101319. https://doi.org/10.1016/j.ghir.2020.101319 - DOI - PubMed
    1. Niculescu DA, Dusceac R, Caragheorgheopol A et al (2019) Disposition index in active acromegaly. Front Endocrinol. https://doi.org/10.3389/fendo.2019.00637 - DOI
    1. Biagetti B, Herance JR, Ferrer R et al (2019) Metabolic fingerprint of acromegaly and its potential usefulness in clinical practice. J Clin Med 8:1549. https://doi.org/10.3390/jcm8101549 - DOI - PMC
    1. Alexopoulou O, Bex M, Kamenicky P et al (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17:81–89. https://doi.org/10.1007/s11102-013-0471-7 - DOI - PubMed

LinkOut - more resources